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Ewing sarcoma
EWSR1-Fli1
ProGRPWe studied a 17-year-old Japanesemalewith hugemass arising from the left third rib. Themass compressed the
left lung and adhered to the pericardium, but the patient had no distantmetastasis. He had a high level of plasma
pro-gastrin-releasing peptide (proGRP). Histopathological examination of the bone biopsy specimen revealed
small round cell tumor which was immunohistochemically positive for CD99 and vimentin. Gene analyses dem-
onstrated EWSR1-FLI1 fusion, conﬁrming the pathological diagnosis of Ewing sarcoma/primitive
neuroectodermal tumor (ES/PNET). Several cycles of chemotherapy resulted in clinical good partial response,
and plasma proGRP level at that timewas normalized. Thereafter residual tumor was resected. Histopathological
examination of the resected specimen showed no viable tumor cells, verifying the pathological complete re-
sponse. High level of plasma proGRP before the chemotherapy and its normalization after the successful chemo-
therapy strongly suggest that ES/PNET in the present case was a proGRP producing tumor.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ewing sarcomas/primitive neuroectodermal tumors (ES/PNETs) are
relatively infrequent but the second most common sarcoma of the
bone next to osteosarcoma. Nearly 80% of them occur in persons youn-
ger than 20 years. Most of them arise from the bone, but 10 to 20% of
them from soft tissue. ES/PNETs are pathologically characterized by
small round cells which often show CD99 expression by immunohisto-
chemistry (IHC). Approximately 85% of them are known to have a recip-
rocal translocation of t(11;22) (q24;q12), which makes EWSR1-FLI1
fusion gene [1]. Other fusion genes including EWSR1-ERG and EWSR1-
ETV1 have also been reported in ES/PNETs [2]. In Ewing-like sarcomas,
fusion genes such as BCOR-CCNB3 [3] and CIC-DUX4 [4] have been dem-
onstrated. Thus, the fusion gene analyses are critical for the deﬁnite di-
agnosis of small round cell tumors including ES/PNETs and Ewing-like
sarcomas.
Pro-gastrin-releasing peptide (proGRP) is a precursor peptide of
GRP, and elevation of serum or plasma GRP level had been reported to
be a useful serological marker for patients with small cell lung cancer
(SCLC) [5]. Because of instability of GRP in plasma, the improved immu-
noassay system to measure a precursor form of GRP, i.e. proGRP, which
is stable in plasma, has been developed [6]. Now, measurement of
serum/plasma proGRP is regarded as a reliable biomarker for SCLC [7].81 798 45 6671.
).
is is an open access article under the CCAlthough serological tumor markers speciﬁc for patients with ES/PNET
are not known, some reports demonstrated that serum CEA [8] or
serum/plasma proGRP was elevated in several patients with ES/PNET.
Elevated serum/plasma proGRP had been reported in two cases of ES/
PNET [9,10]. Moreover, Yamaguchi et al. recently reported that elevated
level of plasma proGRP was detected in 5 out of 9 ES/PNETs [11]. How-
ever, it has been found that expression of GRP in ES/PNETs was not di-
rectly regulated by the EWSR1-FLI1 fusion gene [12].
In this report, we described a rare case of ES/PNET with elevated
level of plasma proGRP. High plasma proGRP level before the chemo-
therapy was normalized after the successful chemotherapy which re-
sulted in clinical good partial response and pathological complete
response. These results strongly suggested that ES/PNET in the present
case was a proGRP producing tumor.
2. Clinical Presentation
A 17-year-old male presented with left chest pain at night. Chest X-
ray and chest computed tomography (CT) demonstrated a 90 × 68 mm
mass arising from the left third rib. For further examinations, the patient
was referred to theDepartment of Orthopedic Surgery, Hyogo College of
Medicine. Chest X-ray and chest CT in our hospital also showed large
tumor with destruction of the cortex of the left third rib (Fig. 1A and
C). The laboratory data showed slightly elevated serum neuron speciﬁc
enolase (NSE) (18.7 ng/ml, normal range: 0–16.3 ng/ml) andmarked el-
evation of plasma proGRP (1310 pg/ml, normal range; 0–81 pg/ml).BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Radiological ﬁndings before and after chemotherapy. A (chest X-ray) and C (chest CT) show that a huge tumorwith destruction of the left third rib is expanding to the left thorax at
the ﬁrst visit to our hospital. B (chest X-ray) and D (chest CT) demonstrate a markedly diminished tumor after chemotherapy.
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nosis, bone biopsy was performed.
3. Materials and methods
3.1. IHC
Resected tissues were ﬁxed in 10% buffered formalin and embedded
in parafﬁn. Three-micrometer-thick sections were cut and stained with
hematoxylin and eosin (H&E). IHC for pankeratin (AE1&AE3, Leica,
Wetzlar, Germany, 1:200), TTF-1 (mouse 8G7G3/1, DAKO, Glostrup,
Denmark, 1:200), vimentin (V9, Leica, 1:400), CD99 (MIC2) (12E7,
DAKO, 1:400), CD56 (NCAM) (1B6, Novocastra, Newcastle, UK, 1:150),
synaptophysin (SY38, DAKO, 1:150) and chromogranin-A (polyclonal,
DAKO, 1:5000) was performed using Bond Polymer Reﬁne Detection
(Leica). IHCs without primary antibodies were performed as negative
controls. Periodic acid Schiff (PAS) stain was also performed with or
without diastase digestion.
3.2. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and
Sequencing
RT-PCR was performed as described previously [13]. Brieﬂy, total
RNA was extracted from fresh frozen surgical material using RNeasy
Mini Kit (Qiagen, Hilden, Germany), and cDNA was synthesized using
SuperScript III reverse transcriptase (Thermo Fisher Scientiﬁc, Wal-
tham, MA). Then, PCR was performed by using MightyAmp DNA poly-
merase (Takara Bio, Otsu, Japan). PCR condition consisted of one cycleof 98 °C for 2 min, and 30 cycles of 98 °C for 10 s and 62 °C for 1 min.
PCR primers were designed according to the previous report [14]. We
used F-EWS 22ex7 (5′-TCCTACAGCCAAGCTCCAAGTC-3′; 1064–1085
in NM_005243) as a forward primer for EWSR1 and R-PARA Fli1 (5′-
GGACTTTTGTTGAGGCCAGA-3′; 1066–1047 in NM_002017) and R-
ERG Q (5′-GGTTGAGCAGCTTTCGACTG-3′; 730–711 in
NM_001136155) as reverse primers for Fli1 and ERG, respectively. As
a control of RNA quality, ampliﬁcation of GAPDH cDNA (110 base
pairs) was done. PCR products were electrophoresed and visualized
on 3% agarose gel using ethidium bromide. All the visible bands were
separately cut from the gel, and DNAs were extracted by QIAquick Gel
Extraction Kit (Qiagen). Each puriﬁed product was directly sequenced
for both directions using forward and reverse primers with ABI BigDye
terminator ver.3.1 (Thermo Fisher Scientiﬁc) and ABI Prism 3100-
Avant Genetic analyzer (Thermo Fisher Scientiﬁc).4. Results
4.1. Clinicopathological Findings
Biopsy specimen showed the clusters of primitive small round cells
with lumen-like structures of various sizes (Fig. 2A). Rosette-like struc-
ture or organoid pattern was not observed. The tumor cells had
glycogenic granules stained with PAS (Fig. 2B) which disappeared
after diastase digestion (data not shown). The tumor cells were positive
for CD99 (Fig. 2C) and vimentin (Fig. 2D), and negative for other
markers such as pankeratin, TTF-1, CD56, synaptophysin and
Fig. 2. Pathological ﬁndings of biopsy specimen. The biopsy specimen reveals small round cells with luminal structures of various sizes (A). The tumor cells have glycogenic granules
stained with PAS (B). The tumor cells are immunohistochemically positive for CD99 (C) and vimentin (D). Bars indicate 100 μm.
15Y. Tsukamoto et al. / Human Pathology: Case Reports 6 (2016) 13–18chromogranin-A. These pathological ﬁndings were typical for those of
ES/PNET as described [15].
4.2. RT-PCR and Sequencing
By RT-PCR using primers F-EWS22 ex7 and R-PARA Fli1, a DNA frag-
ment about 129 base pair length was observed. By sequencing of the
DNA fragment, the fusion of EWSR1 exon 7 (NM_005243) and FLI1
exon 6 was observed (Fig. 3). This fusion pattern is referred to as type
1 by Gamberi et al. [14]. This type is the most common in ES/PNETs.
4.3. Clinical follow-up information
Following the diagnosis of ES/PNET, a chemotherapy regimen of
6 cycles of VDC/IE (vincristine 2 mg/m2, doxorubicin 75 mg/m2 and cy-
clophosphamide 1200 mg/m2 with ifosfamide 1800 mg/m2/day ×
5 days and etoposide 100 mg/m2/day × 5 days) [16] was administered
for 14 months. Following chemotherapy, chest X-ray and chest CT
showed marked tumor reduction (Fig. 1B and D) which was evaluated
as clinical good partial response, and the plasma proGRP level wasFig. 3.Gene analysis for EWSR1-FLI1 fusion. Sequencingof the ampliﬁedPCRproduct shows the
between EWSR1 and FLI1.normalized (56.1 pg/ml). Therefore, surgical removal of the tumor
was done. Fig. 4A shows the gross ﬁnding of resected material and
Fig. 4B shows the cut surface of it. In the center of the resected sample,
cavity-like necrotic area was observed. Histopathologically, cortex of
the third rib bone was destroyed (Fig. 4C), and ﬁbrous scar tissue was
seen not only in the bone (Fig. 4C, left side) but also outside the bone
(Fig. 4C, right side). Granulation tissue was observed outside the bone
(Fig. 4D). Residual tumor cells were not apparent in the whole resected
specimen, conﬁrming the pathological complete response. The patient
is alive without disease recurrence 26 months after the ﬁrst visit to
our hospital.
5. Discussion
It is very rare that elevated serological tumormarkers are detected in
ES/PNET cases. In the case of serum CEA, only one case of 7-year-old boy
with skull ES/PNET has been reported (91.09 ng/ml) [8]. In the case of
proGRP, on the other hand, only 7 caseswith ES/PNET have been report-
ed [9–11]. Takagi-Takahashi et al. reported a case of 69-year-old man
with ES/PNET of chest wall (serum proGRP 754 pg/ml, normal range:fusion of EWSR1 exon7 (NM_005243) and FLI1 exon6. An arrow indicates the fusion point
Fig. 4. Pathological ﬁndings of surgical material. Gross ﬁnding of surgical material (A) and cut surface of it (B) are shown. Cortex of the third rib bone is destructed (C), and ﬁbrous scar
tissue is seen not only in the bone (C, left side) but also outside the bone (C, right side). Granulation tissue is observed outside the bone (D). Residual tumor cell is not apparent in the
whole resected specimen. Bars indicate 500 μm.
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sociated with abdominal dissemination and multiple liver metastases
(plasma proGRP 3725 pg/ml, normal range; 0–81 pg/ml) [10]. The pa-
tient died of disease progression with the increased level of plasma
proGRP (9970 pg/ml). Yamaguchi et al. reported 5 cases of ES/PNET
with high levels of serum proGRP (96–683 pg/ml, normal range
0–46 pg/ml) [11]. They consisted of 2 males and 3 females between
the age of 19 and 58 [11]. Two cases were arising from the bone and 3
from soft tissue of the thorax [11]. Therefore, to our knowledge, this is
the 8th case of ES/PNET with serologically elevated proGRP (1310 pg/
ml in plasma). In the present case, normalization of plasma proGRP
level was observed after chemotherapy which resulted in pathological
complete response. These ﬁndings strongly suggested that ES/PNET in
our case was a proGRP producing tumor. In cases of ES/PNET with ele-
vated serum/plasma proGRP, follow-up information of proGRP level is
available in only two cases; one is a case reported by Yamamoto et al.
[10] and the other is the present case. Ours is the only one case showing
the normalization of plasma proGRP level after chemotherapy.
To our knowledge, immunohistochemical analysis for proGRP was
done in 5 cases [9,10,17,18]. Takagi-Takahashi et al. reported that the
tumor cells were positive for proGRP in one case [9]. Yamaguchi et al.
also showed that tumor cells in two patients of ES/PNET with elevated
serum proGRP were positive for proGRP [10]. On the other hand, in
one of the two cases of pulmonary PNET without elevation of serum
proGRP level reported by Imamura et al. [17], tumor cells were
immunohistochemically negative for proGRP. And also Mikami et al. re-
ported a case of pulmonary PNET which was negative for proGRP in
both serum and tumor cells [18]. In our case, IHC for proGRP was not
performed.
Since our case was young, high level of serum/plasma proGRP un-
likely meant that the chest tumor was SCLC. In older patients, on the
other hand, elevated serum/plasma proGRP strongly suggests that the
chest tumor could be SCLC. However, there is a possibility that
middle-aged or even rather old people are affected by ES/PNETs. Since
the tumor cells of ES/PNET are somewhat reminiscent of those of
SCLC, ES/PNET cases arising from the thorax in older patients withelevated serum/plasma proGRP level might be erroneously diagnosed
as SCLCs and treated as SCLCs like a case of Takagi-Takahashi et al. [9].
Careful pathological examination including appropriate IHC and genetic
analyses is recommended in such situation.
The number of ES/PNET cases in which serum/plasma proGRP level
was examined is unclear and the frequency of blood proGRP elevation
in all ES/PNET patients also remains to be clariﬁed. Therefore, the signif-
icance and the regulatory mechanism of proGRP production remain to
be elucidated in ES/PNETs. Considering that both CEA and proGRP are
expressed by primitive cells during embryonal and developmental
stages [19,20], expression of such markers with high serum/plasma
level might indicate the primitive nature of ES/PNETs.
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